单中心回顾性研究:局部晚期宫颈癌单次置入4次分割高剂量率近距离放疗的疗效、可行性及预后因素
本研究回顾性分析2014年1月至2021年12月在本院治疗的139例局部晚期宫颈癌(FIGO 2018 IB-IVB)患者,接受外照射45-50.4 Gy同步化疗后行单次置入4次分割高剂量率近距离放疗(24 Gy)。136例(98%)可完成近距离放疗方案,中位随访40.5个月,2年局部控制率79.4%、总生存率77.7%、无病生存率61.7%。
要点
- 单次置入4次分割高剂量率近距离放疗在98%(136/139)的局部晚期宫颈癌患者中可完成。
- 近距离放疗前MRI评估的肿瘤对外照射的反应是局部控制的独立预后因素。
- 宫旁受侵与无病生存显著相关(P = .04),与总生存也显著相关(P = .01)。
核心结论
- 单次置入4次分割高剂量率近距离放疗可在98%的局部晚期宫颈癌患者中实施,局部控制率和总生存率良好,毒性可耐受。
- 近距离放疗前MRI评估的初始放化疗反应是重要预后因素,可能有助于个体化治疗策略。
研究设计与样本
- 单中心回顾性分析2014年1月至2021年12月在本院治疗的局部晚期宫颈癌(FIGO 2018 IB-IVB)患者139例。
- 患者均接受根治性放疗,外照射剂量45-50.4 Gy,同步化疗,高剂量率近距离放疗处方剂量24 Gy至高危临床靶区。
主要发现
- 136例(98%)可完全执行高剂量率近距离放疗方案。
- 中位随访40.5个月,2年局部控制率79.4%、总生存率77.7%、无病生存率61.7%;5年局部控制率78.2%、总生存率61.6%、无病生存率55.7%。
- 多因素分析显示局部控制的主要决定因素为近距离放疗前MRI评估的肿瘤对外照射的反应。
- 宫旁受侵与无病生存显著相关(P = .04);宫旁受侵(P = .01)和放化疗后肿瘤反应(P = .02)与总生存显著相关。
- 18%(25例)发生3级慢性并发症;D2cc(肠)阈值为70 Gy(P = .001)可限制3级及以上慢性消化道并发症。
关键数值与推荐
- 高剂量率近距离放疗处方剂量为24 Gy至高危临床靶区。
- 外照射剂量为45-50.4 Gy,同步化疗。
- D2cc(肠)最佳阈值为70 Gy(P = .001)以限制3级及以上慢性消化道并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to assess the feasibility and efficacy of high-dose rate (HDR) brachytherapy (BT) administered in a single insertion with 4 treatment sessions for locally advanced cervical cancer and to identify the prognostic factors influencing outcomes. METHODS AND MATERIALS: We retrospectively analyzed the clinical data of patients with cervical cancer with locally advanced disease (International Federation of Gynecology and Obstetrics 2018 IB-IVB) treated at our institution from January 2014 through December 2021. Each patient received definitive radiation therapy with an external irradiation dosage between 45 and 50.4 Gy along with concurrent chemotherapy. HDR-BT (24 Gy) was prescribed to a high-risk clinical target volume. RESULTS: One hundred thirty-nine patients were included and the HDR-BT program could be fully performed in 136 patients (98%). Over a median follow-up duration of 40.5 months, the 2-year local control (LC), overall survival (OS), and disease-free survival rates stood at 79.4%, 77.7%, and 61.7%, respectively, with 5-year rates at 78.2%, 61.6%, and 55.7%. Multivariate analysis revealed the primary determinant of LC as the tumor's response to external beam radiation therapy as determined via magnetic resonance imaging before BT. Parametrial involvement demonstrated a significant multivariate association with disease-free survival (P = .04). Regarding OS, parametrial invasion (P = .01) and the tumor's response postchemoradiotherapy (P = .02) emerged as significant factors. Regarding chronic toxicities, 18% (25 patients) experienced grade 3 complications. An optimal D2 cc (bowel) threshold of 70 Gy (P = .001) was identified to limit chronic digestive complications of grade 3 or higher. CONCLUSIONS: The implementation of single-insertion, 4-session HDR-BT could be performed in 98% of the patients. It yields favorable LC and OS rates, coupled with tolerable toxicity in patients with locally advanced cervical cancer. Response to initial chemoradiotherapy evaluated on pre-BT magnetic resonance imaging is an important prognostic factor and could help to individualize therapeutic strategies.
引用
- Houdou L, Meynard C, Guillerm S, et al. Monocentric Retrospective Study: Efficacy, Feasibility, and Prognostic Factors of Single-Insertion High-Dose-Rate Brachytherapy With 4 Sessions for Locally Advanced Cervical Cancer. Adv Radiat Oncol. 2024. PMID: 38883995. doi:10.1016/j.adro.2024.101512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。